...
首页> 外文期刊>HIV medicine >Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.
【24h】

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

机译:在多地点加拿大队列中,在高活性抗逆转录病毒疗法中,HIV阳性个体的病毒学抑制相关因素。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The aim of the study was to evaluate time to virological suppression in a cohort of individuals who started highly active antiretroviral therapy (HAART), and to explore the factors associated with suppression. METHODS: Eligible participants were HIV-positive individuals from a multi-site Canadian cohort of antiretroviral-naive patients initiating HAART on or after 1 January 2000. Viral load and CD4 measurements within 6 months prior to HAART initiation were assessed. Univariate and multivariate analyses were conducted using piecewise survival exponential models where time scale was divided into intervals (<10 months; >/=10 months). Virological suppression was defined as the time to the first of at least two consecutive viral load measurements <50 HIV-1 RNA copies/mL. RESULTS: A total of 3555 individuals were included in the study, of median age 40 years [interquartile range (IQR) 34-47 years]. Eighty per cent were male, 18% had a history of injecting drug use (IDU), and 13% presented with an AIDS-defining illness at baseline. The median time to suppression was 4.55 months (IQR 2.99-7.89 months). In multivariate analyses, older age, male sex, treatment in Ontario rather than British Columbia, non-IDU history, and having an AIDS diagnosis at baseline predicted increased likelihood of suppression. Patients with low baseline viral load were more likely to have suppression [4-5 log(10) copies/mL, hazard ratio (HR) 1.27, 95% confidence interval (CI) 1.18-1.38; <4 log(10) copies/mL, HR 1.49, 95% CI 1.32-1.68] than patients with baseline viral load >/=5 log(10) copies/mL; however, this effect ceased after 18 months of follow-up. Suppression was more likely with nonnucleoside reverse transcriptase inhibitors and ritonavir-boosted HAART. CONCLUSION: Identification of patients at risk for diminished likelihood of virological suppression will allow focusing of efforts and the utilization of resources to maximize the benefits of HAART.
机译:目的:该研究的目的是评估开始高活性抗逆转录病毒疗法(HAART)的人群中病毒抑制的时间,并探讨与抑制相关的因素。方法:符合条件的参与者是来自2000年1月1日或之后开始接受HAART的加拿大多地点抗逆转录病毒初治患者队列的HIV阳性患者。评估了开始HAART之前6个月内的病毒载量和CD4含量。使用分段生存指数模型进行单因素和多因素分析,其中将时间尺度分为间隔(<10个月;> / = 10个月)。病毒学抑制作用被定义为至少两次连续的病毒载量测量中第一次<50 HIV-1 RNA拷贝/ mL的时间。结果:该研究共纳入3555名个体,中位年龄为40岁[四分位间距(IQR)34-47岁]。男性占80%,有注射吸毒史(IDU)占18%,基线时有AIDS定义疾病。中位抑制时间为4.55个月(IQR 2.99-7.89个月)。在多变量分析中,年龄,男性,在安大略省而不是不列颠哥伦比亚省的治疗,非注射毒品者的病史以及基线诊断为艾滋病可预示抑制的可能性增加。基线病毒载量低的患者更有可能受到抑制[4-5 log(10)拷贝/ mL,危险比(HR)1.27,95%置信区间(CI)1.18-1.38;与基线病毒载量> / = 5 log(10)拷贝/ mL的患者相比,<4 log(10)拷贝/ mL,HR 1.49,95%CI 1.32-1.68];但是,经过18个月的随访,这种作用停止了。使用非核苷类逆转录酶抑制剂和利托那韦增强的HAART抑制的可能性更高。结论:确定有病毒抑制可能性降低风险的患者将允许集中精力和利用资源以最大化HAART的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号